KIEONCT05977907
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 46 days later.
See at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion pushed from Oct 16, 2026 to Dec 2026
Notable Eligibility criteria expanded, about 33 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised at 5 of 5 sites
- Collaborators: details revised at 1 of 2 entries
- Notable Enrollment target: 15 to 30v8
- Minor Start date changed from estimate of Dec 1, 2023 to Dec 14, 2023v4
- Notable Start date: Oct 16, 2023 to Dec 1, 2023v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Start date: Sep 1, 2023 to Oct 16, 2023
- Study sites: 1 to 5
- Primary completion date: Sep 1, 2026 to Oct 16, 2026
- Study completion date: Sep 1, 2028 to Oct 16, 2028
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pathologic Treatment Response rate
Timeframe: From neoadjuvant therapy to surgical resection, up to 6 weeks
Secondary (5)
Major Pathologic Response
Disease progression
Overall survival
Overall Safety
ctDNA in comparison to other neoadjuvant treatments
Arms and interventions
Single CohortExperimental
Neoadjuvant Pembrolizumab ( 400mg IV infusion x1) + IO102-103 ( Subcutaneous injection weekly x6) Adjuvant Pembrolizumab ( 400 mg IV infusion Every 6 weeks x8) + IO102-103 ( Subcutaneous injection every 3 week x6 then every 6 weeks x5)
Drugs: Pembrolizumab, IO102-103
Sites
5 sites in 1 country